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Background: NBPF1 (Neuroblastoma Breakpoint Family, member 1) was originally identified in a neuroblastoma
patient on the basis of its disruption by a chromosomal translocation t(1;17)(p36.2;q11.2). Considering this genetic
defect and the frequent genomic alterations of the NBPF1 locus in several cancer types, we hypothesized that
NBPF1 is a tumor suppressor. Decreased expression of NBPF1 in neuroblastoma cell lines with loss of 1p36
heterozygosity and the marked decrease of anchorage-independent clonal growth of DLD1 colorectal carcinoma
cells with induced NBPF1 expression further suggest that NBPF1 functions as tumor suppressor. However, little is
known about the mechanisms involved.
Methods: Expression of NBPF was analyzed in human skin and human cervix by immunohistochemistry. The effects
of NBPF1 on the cell cycle were evaluated by flow cytometry. We investigated by real-time quantitative RT-PCR the
expression profile of a panel of genes important in cell cycle regulation. Protein levels of CDKN1A-encoded p21CIP1/WAF1
were determined by western blotting and the importance of p53 was shown by immunofluorescence and by a loss-of-
function approach. LC-MS/MS analysis was used to investigate the proteome of DLD1 colon cancer cells with
induced NBPF1 expression. Possible biological interactions between the differentially regulated proteins were
investigated with the Ingenuity Pathway Analysis tool.
Results: We show that NBPF is expressed in the non-proliferative suprabasal layers of squamous stratified epithelia of
human skin and cervix. Forced expression of NBPF1 in HEK293T cells resulted in a G1 cell cycle arrest that was
accompanied by upregulation of the cyclin-dependent kinase inhibitor p21CIP1/WAF1 in a p53-dependent manner.
Additionally, forced expression of NBPF1 in two p53-mutant neuroblastoma cell lines also resulted in a G1 cell cycle
arrest and CDKN1A upregulation. However, CDKN1A upregulation by NBPF1 was not observed in the DLD1 cells, which
demonstrates that NBPF1 exerts cell-specific effects. In addition, proteome analysis of NBPF1-overexpressing DLD1 cells
identified 32 differentially expressed proteins, of which several are implicated in carcinogenesis.
Conclusions: We demonstrated that NBPF1 exerts different tumor suppressive effects, depending on the cell line
analyzed, and provide new clues into the molecular mechanism of the enigmatic NBPF proteins.
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We originally identified human NBPF1 (Neuroblastoma
BreakPoint Family, member 1) in a neuroblastoma (NB)
patient on the basis of its disruption in a de novo, consti-
tutional translocation between chromosomes 1p36.2 and
17q11.2 [1-3]. NBPF1 is a member of a gene family with
intricate genomic structure [4]. The NBPF members are
primarily located on duplicated regions of chromosome
1, and analysis of the predicted protein sequences showed
that several pairs of exon types encode a protein domain
called the NBPF/DUF1220 repeat [4, 5]. The number of
encoded NBPF/DUF1220 repeats varies from 4 to 52 cop-
ies, depending on the gene member and the NBPF1 pro-
tein has 7 repeats [6]. The copy number of the NBPF/
DUF1220 repeat is much larger in humans than in other
primates, which suggests an important role in human evo-
lution [4, 5]. The NBPF genes are likely involved in cancer
and in brain and developmental disorders (reviewed in
[7]). This has been ascribed to their location in unstable
high-identity duplication blocks, which leads to recurrent
chromosomal rearrangements. One tumor type of particu-
lar interest is NB.
NB tumors are derived from the sympathetic nervous
system and account for approximately 15% of cancer
deaths in children [8]. However, a fascinating feature of
NB is its remarkable biological heterogeneity, which is
evident in the broad variety of clinical courses of the dis-
ease. While some patients experience spontaneous re-
gression or differentiation of the tumor, others are
affected by rapid and fatal tumor progression despite in-
creasingly intensive treatment strategies [9].
Evidence for the involvement of NBPF genes in NB
comes from the abovementioned disruption of NBPF1 in
a NB patient, and from the association of NB with copy
number variation of an NBPF1 paralog [10]. Interest-
ingly, the 1p36 region is frequently deleted not only in
NB, but also in other human cancer types, including
those of neural, epithelial and hematopoietic origin, indi-
cating that the same tumor suppressor genes might be
involved in a broad range of human cancers [11].
Based on these findings, we hypothesized that NBPF1
acts as a tumor suppressor. Previously, we reported that
expression of NBPF1 mRNA is significantly decreased in
NB cell lines with loss of heterozygosity for 1p36 com-
pared to cell lines with a normal 1p36 locus [3]. This de-
creased expression is a hallmark of tumor suppression
activity. Moreover, NBPF1-expressing colon cancer cells
formed significantly fewer colonies in soft agar than con-
trol cell lines, indicating that NBPF1 might be important
for suppression of anchorage-independent growth [3].
In this study, we show that NBPF is expressed in the
non-proliferative suprabasal layers of squamous stratified
epithelia of human skin and cervix. Moreover, we show
that forced expression of NBPF1 in the human HEK293Tcell line resulted in a p53-dependent G1 cell cycle arrest
that was accompanied by upregulation of the cyclin-
dependent kinase inhibitor p21CIP1/WAF1. Additionally,
overexpression of NBPF1 in two p53-mutant NB cell lines
resulted in G1 cell cycle arrest and concomitant CDKN1A
induction. However, G1 cell cycle arrest and CDKN1A up-
regulation were not observed in a colon cancer cell line in
which NBPF1 expression was induced, despite the clear
NBPF1-dependent inhibition of anchorage-independent
clonal growth in this cell line [3]. This demonstrates that
NBPF1 exerts cell-specific tumor suppressive effects. In
conclusion, this study advances the understanding of the
role of NBPF1 as a tumor suppressor.
Methods
Reagents
Doxycycline hydrochloride (dox; Sigma, Bornem, Belgium)
was used at a final concentration of 2 μg/ml to induce
expression of NBPF1-IRES-EGFP or EGFP in DLD1Tr21/
NBPF1 and DLD1Tr21/Mock cells, respectively. Doxorubi-
cine hydrochloride (Doxo; Sigma) was used at a final con-
centration of 350 nM during 24 h. Aphidicolin (Sigma)
was used at a final concentration of 2 μg/ml.
Cell culture and transfections
Human HEK293tsA1609neo (in short HEK293T) and its
derivative HEK_shRNAp53 (in which the expression of
p53 has been silenced by an shRNA) were cultured in
DMEM medium supplemented with 10% fetal calf serum
(FCS), 2 mM glutamine and 0.4 mM sodium pyruvate.
SH-SY5Y neuroblastoma cells (ATCC, CRL-2266) were
cultured in DMEM medium supplemented with 15%
FCS, 2 mM glutamine and 0.4 mM sodium pyruvate.
The SK-N-AS (ATCC, CRL-2137) and NLF [12] neuro-
blastoma cell lines were cultured in RPMI medium sup-
plemented with 10 % FCS, 2 mM glutamine and 0.4 mM
sodium pyruvate. HEK293T cells were transfected using
the calcium phosphate precipitation method, and neuro-
blastoma cells were transfected with Fugene HD (Roche
Applied Science, Vilvoorde, Belgium). DLD1Tr21/Mock
and DLD1Tr21/NBPF1 cells have been described and
were grown in standard medium composed of RPMI with
10% FCS [3].
Plasmid constructions
To construct the pdEGFP-NBPF1 plasmid for expression
of EGFP-fused NBPF1 under the control of a CMV pro-
moter, full-length NBPF1 cDNA was transferred to the
pdEGFP vector by Gateway technology (Life Technolo-
gies Europe, Ghent, Belgium). The vector expressing
EGFP-luciferase under the control of an SV40 promoter
(pGL3-EGFP-luciferase) was a kind gift from Dr. Eric
Raspé. To generate DLD1Tr21/NBPF1 cells, we cloned
cDNA of NBPF1-IRES-EGFP, fused to an amino-terminal
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Europe). This plasmid expresses flag-tagged NBPF1, under
the control of a doxycycline-inducible promoter [3].
Immunofluorescence
Cells on glass coverslips were rinsed briefly with PBS
and fixed with 4% paraformaldehyde. They were incu-
bated for 1 h with primary antibody diluted in blocking
solution (0.4% gelatin). Antibodies used were goat anti-
NBPF sc-82241 (Santa Cruz Biotechnology, Heidelberg,
Germany, dilution 1/200) and mouse anti-p53 DO-1
(Santa Cruz Biotechnology, dilution 1/250). Cells were
then washed in PBS and incubated for 1 h with second-
ary antibodies coupled to Alexa fluorophores (Life Tech-
nologies Europe) diluted in blocking solution. Coverslips
were mounted in Vectashield containing DAPI (Vector
Laboratories, Peter Borough, United Kingdom) to pre-
vent photobleaching.
SDS-PAGE and immunoblotting
EGFP-positive and EGFP-negative populations of HEK293T,
HEK293T_shRNAp53, SH-SY5Y, NLF and SK-N-AS cells
were isolated at 48 h after transfection by FACS (Epics Altra,
Beckman Coulter, California, USA) and used for protein ex-
traction with Trizol (Life Technologies Europe). For subse-
quent SDS-PAGE analysis we used a 10 % gel and loaded a
total of 40 μg protein per lane. After blotting to PVDFmem-
branes (Millipore, Billerica, MA, USA), blocking with 5 %
non-fat dry milk occurred. The membrane was washed 3
times with 5%w/v BSA, 1xTBS, 0.1%Tween® 20 and then in-
cubated overnight with primary anti-p21CIP1/WAF1 antibody
(rabbit anti-p21CIP1/WAF1 12D1, Cell Signaling Technology,
Beverly, MA, USA; dilution 1/1000) in the same buffer at 4 °
C. After several washings, the membrane was incubated for
1 h with secondary horseradish peroxidase (HRP)-conju-
gated antibodies and proteins were detected by the enhanced
chemiluminescence (ECL) detection system (GE Healthcare
Europe, Diegem, Belgium). Anti-vinculin (mouse anti-
vinculin, Sigma, dilution 1/1000) or anti-actin (mouse anti-
actin,MP Biomedicals, dilution 1/10.000) detection was used
as a loading control and anti-EGFP (rabbit anti-GFPA11122,
Life Technologies, dilution 1/1000) or anti-NBPF detection
(sc-82241, dilution 1/1000) was used to confirm transfection
efficiency or in cell sorting experiments.
Immunohistochemistry on paraffin-embedded tissue
sections
Formalin-fixed, paraffin-embedded tissue specimens were
retrieved from the archives of the Pathology Department
at the University Hospital of Liège (protocol approved by
the Liège University Hospital Ethics Committee). No
other ethical approval was required for this study. Human
and mouse tissues were fixed in 4% paraformaldehyde,
dehydrated and paraffin-embedded. For staining, paraffinwas removed and sections were rehydrated. Endogenous
peroxidase was blocked with a 1/100 dilution of H2O2 in
methanol. Antigen retrieval was carried out in a pressure
cooker (2100 Retriever, PickCell Laboratories, Amsterdam,
The Netherlands) with the sections soaked in citrate re-
triever buffer. Aspecific binding sites were blocked with
3 % horse serum in PBS + 1% BSA. Incubation with pri-
mary antibody (sc-82241, diluted 1/200 in PBS/1 % BSA)
was done overnight at 4°C. Incubation with biotinyl-
ated secondary antibody (Dako, Glostrup, Denmark,
dilution 1/300) was carried out for 30 min at room
temperature. This was followed by a 20-min incubation
with StreptABComplex/HRP (Dako) according to the
manufacturer’s protocol. After washing, the sections
were treated with DAB (BioGenex, Fremont, CA, USA)
and counterstained with hematoxylin following stand-
ard procedures. Finally, the sections were embedded in
Pertex (HistoLab, Gothenburg, Sweden).
Time-lapse microscopy
HEK293T cells were transfected in an eight-well LabTek
II chamber glass slide (Sigma) with plasmids encoding
either EGFP-NBPF1 or EGFP-luciferase. After 6 h, the
transfection medium was replaced with fresh medium
and in one set of experiments aphidicolin was added
after 24 h. At 48 h after transfection, EGFP-positive cells
were selected for time-lapse recording using a cell obser-
ver spinning disk system (Zeiss, Zaventem, Belgium).
This system includes an observer Z.1 microscope
equipped with a Yokogawa disk CSU-X1. Images were
taken with a pln Apo 40x/1.4 oil DIC III objective and a
Rolera em-c2 Camera. The setup includes an incubation
chamber, maintained at 37°C in a 5% CO2 atmosphere.
DIC and fluorescence images were obtained every
10 min for 15 h. Images were processed into movies
using Fiji (Just ImageJ; http://pacific.mpi-cbg.de/).
Cell cycle analysis
Cells were harvested 48 h after transfection and fixed for
1 h in ice-cold ethanol. Fixed cells were treated with
RNase A (Sigma, 1 mg/ml) and stained with propidium
iodide (Sigma, 50 μg/ml). The cellular DNA content of
EGFP-positive and EGFP-negative populations was evalu-
ated using flow cytometry (FACSVerse; Becton Dickinson,
San Jose, California, USA). We applied software-based
compensation (Flowjo) to the collected data. Compensa-
tion matrix was defined with reference to single color con-
trols. Gating strategy: 1/ side scatter versus forward
scatter to exclude debris; 2/ FSC-height versus FSC-area
for doublet discrimination; 3/ EGFP (FITC) versus for-
ward scatter to identify EGFP-negative and EGFP-positive
subpopulations. Cells with very strong EGFP expression
were not taken into account for cell cycle analysis because
time lapse experiments had shown that cells with such
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considered these EGFP levels as not physiological. All ex-
periments were performed at least three times, and one
representative figure is shown.
Real-time qRT-PCR
EGFP-positive and EGFP-negative populations of HEK293T
and HEK293T_shRNAp53 cells were isolated at 48 h after
transfection by FACS (Epics Altra, Beckman Coulter,
California, USA) and used for RNA extraction and real-
time qRT-PCR analysis. RNA was prepared from the dif-
ferent cell populations with Trizol (Life Technologies
Europe). cDNA was prepared with the iScript cDNA syn-
thesis kit according to the manufacturer's instructions
(Bio-Rad). qRT-PCR mixes contained 20 ng template
cDNA, SensiFast SYBR No-ROX kit (GC Biotech, Alphen
aan den Rijn, The Netherlands) and 300 nM forward and
reverse primers. Reactions were performed on a LightCy-
cler 480 (Roche) using the following protocol: incubation
at 95°C for 5 min, followed by 40 cycles: 95°C for 10 s, 60°C
for 30 s, and 72 °C for 1 s. Primers used are listed in Table 1.
Gene expression levels were normalized using the geomet-
ric mean of the most stable reference genes [13].
Proteome analysis
DLD1Tr21/Mock and DLD1Tr21/NBPF1 cells were
grown for 4 days in their standard medium, containing
2 μg/ml dox. Cell pellets were re-suspended in 0.5 ml ofTable 1 List of primer sequences used for quantitative RT-PCR of th
Gene Forward (5' to 3')
ANAP2 GACAGGAGTTGTTAGTGGCCT
ATM ACGTTACATGAGCCAGCAAAT
ATR TCTCAGCCAACCTCCGTGAT
CCND1 GTGCTGCGAAGTGGAAACC
CCNE1 GAGCCAGCCTTGGGACAATAA
CDC34 GACGAGGGCGATCTATACAACT
CDK2 GCTAGCAGACTTTGGACTAGCC
CDK4 ATGTTGTCCGGCTGATGGA
CDK6 GCGCCTATGGGAAGGTGTTC
CDKN1A CGCTAATGGCGGGCTG
CDKN1B CTGCAACCGACGATTCTTCTACT
CUL1 ACCAGTCAAACCAAGCACGAG
CUL2 ACGACAATAAAAGCCGTGGTC
CUL3 TGTGGAGAACGTCTACAATTTGG
SKP2 ACCTCCAGGAGATTCCAGACC
TP53 CCTCAGCATCTTATCCGAGTGG
NBPF1 GCGAGGCTGCCCGAGCTTCT
EGFP GAGCTGAAGGGCATCGACTTcell lysis buffer (50 mM sodium phosphate, pH 7.5,
100 mM NaCl, 0.8% (w/v) CHAPS, and Complete Prote-
ase Inhibitor cocktail (Roche)). The insoluble fraction was
removed by centrifugation (15 min at 16.000 g at 4°C).
Samples were desalted on a NAP5 column in 20 mM tri-
ethylammonium bicarbonate (pH 7.0). Endoproteinase
Lys-C digestion was carried out at 37°C overnight using a
ratio of 1/100 (w/w) endoproteinase Lys-C/protein. Pep-
tides from the DLD1Tr21/Mock cell lysate were post-
metabolically labeled with light NHS-12C3-propionate,
whereas the peptides from DLD1Tr21/NBPF1 cell lysate
were labeled with heavy NHS-13C3-propionate. Equal
amounts of the peptide mixtures were combined, concen-
trated by vacuum-drying and re-dissolved in 1% acetic
acid. The peptide mixture was then separated by RP-
HPLC chromatography and 20 fractions were collected
for further LC-MS/MS analysis. LC-MS/MS analysis was
done on a LTQ-Orbitrap mass spectrometer. We acquired
158,141 MS/MS spectra, from which we identified 13,315
unique peptides (Swiss-Prot database, restriction to hu-
man proteins) and 3613 proteins (Mascot software used at
99% confidence). Mascot Distiller was then used to quan-
tify the proteins and only proteins with a minimum of two
quantifiable peptides in the experiment were included in
the Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
Redwood City, CA). Keratins and ribosomal proteins were
considered non-specific and were excluded from IPA
analysis.e genes indicated
Reverse (5' to 3')
TCCAGGACCGAGTGTAGCC
GAAAATGAGGTGGATTAGGAGCA
GCAGAAGTCTCGTTATGATCCAA
ATCCAGGTGGCG ACGATCT
GCACGTTGAGTTTG GGTAAACC
GAGTATGGGTAGTCGATGGGG
AG AGCTCGGTACCACAGGGTCA
CACCAGGGTTACCTTGATCTCC
TTGGGGTGCTCGAAGGTCT
CGGTGACAAAGTCGAAGTTCC
GGGCGTCTGCTCCACAGA
GTCTGCCCCTTTTTCGACTTAG
GGTTCAGGATAGGCCACACATA
TGCGCCTCTGTCTACGACT
CCCAGGTTTGAGAGCAGTTCC
TGGATGGTGGTACAGTCAGAGC
GACTTCGCGTAACTTCCCATTCA
TCTGCTTGTCGGCCATGAT
Fig. 1 Polyclonal antibody sc-82241 recognizes NBPF proteins specifically and detects NBPF expression in suprabasal layers of normal human skin
and cervix. (A) Upon overexpression of NBPF1, fused to EGFP, in HEK293T cells, a clear overlap is detected between the EGFP signal and the signal
of the anti-NBPF antibody sc-82241. Nuclei were stained with DAPI. Scale bar: 10 μm. (B) The anti-NBPF antibody yields a specific cytoplasmic
staining in DLD1Tr21/NBPF1 cells when NBPF1 expression is induced in the presence of dox. Scale bar: 10 μm. (C) Paraffin sections from human
(left panel) and mouse skin (right panel) were stained with anti-NBPF antibody sc-82241. In the human epidermis, staining for NBPF is observed
only in the non-proliferating, differentiated cells of the suprabasal layer and not in the proliferating basal cell layer (arrows). The middle panel
shows a magnification of the boxed area. Mouse skin served as a negative control: no staining is seen in any of the living layers of the epidermis.
The cornified envelope of the epidermis shows aspecific staining, since the signal is obtained in both mouse and human samples. Scale bars:
25 μm. (D) Normal human cervix stained with anti-NBPF antibody sc-82241 shows strong immunopositivity of the suprabasal layer. The middle
panel shows a magnification of the boxed area. In the negative control (right panel), the primary antibody was omitted. Arrows point to basal cell
layers. Scale bars: 25 μm
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Fig. 2 Time-lapse microscopy of NBPF1 expression in transfected HEK293T cells. Expression of EGFP-luciferase or EGFP-NBPF1 was followed for
15 h with images captured every 10 min. Individual frames are shown. Original movies are available as Additional files 1 and 2. Fluorescence levels
are represented by pseudocolors, where blue indicates low EGFP levels and yellow indicates high EGFP levels (ImageJ LUT; color codes shown at
the bottom). (A) Expression of EGFP-luciferase in cells remained at a constant level at all the indicated time points and did not interfere with cell
division or induce cell death. The arrow points to an EGFP-positive mitotically dividing cell. (B) Expression of EGFP-NBPF1 in cells fluctuated, with
some cells showing decreasing levels and others showing delayed expression. In no case were EGFP-NPBP1 expressing mitotic cells observed
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Fig. 3 Time-lapse microscopy of NBPF1 expression in transfected HEK293T cells stimulated with aphidicolin. EGFP-luciferase or EGFP-NBPF1 expression
was followed for 15 h with images captured every 10 min. Individual frames are shown. Original movies are available as Additional files 3 and 4.
Fluorescence levels are represented by pseudocolors, with blue indicating low EGFP levels and yellow indicating high EGFP levels (ImageJ LUT; color
codes shown at the bottom). (A) Expression of EGFP-luciferase in cells stimulated with aphidicolin remained at a constant level at all the indicated
time points. (B) Expression of EGFP-NBPF1 in cells stimulated with aphidicolin showed increased accumulation in the form of particulate or aggregated
structures. In no case were cells with decreasing levels of EGFP-NBPF1 observed
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Fig. 4 NBPF1 inhibits cell cycle progression in transfected HEK293T cells. HEK293T cells were transfected with plasmids encoding either EGFP-luciferase
(negative control) or EGFP-NBPF1. Cell cycle profiles were determined 48 h after transfection by flow cytometry on the effectively transfected
(EGFP-positive) cell subpopulations. Transfection efficiency is represented as percentages in the left panels. The different cell cycle phases are
shown only for the effectively transfected (EGFP-positive) subpopulations (right panels). Cells in G1 phase (2n DNA content) and cells in G2
phase (4n DNA content) are annotated on the histograms and calculated as percentage of the whole population
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NBPF members are expressed in the suprabasal layers of
squamous stratified epithelia
To explore the expression of the NBPF family members
in more detail, we detected endogenous NBPF proteins
in paraffin-embedded sections of human skin and cervix
using a commercially available polyclonal anti-NBPFantibody (sc-82241). This antibody is raised against a pep-
tide located in the protein domain encoded by exon types
5 and 1 (amino acids 240–290, UniProtKB Q3BBV1) and
recognizes several NBPF proteins, including NBPF1. Be-
cause only few anti-NBPF antibodies are commercially
available, it was important to confirm the specificity of this
particular antibody. In immunofluorescence experiments,
Fig. 5 EGFP-luciferase and EGFP-NBPF1 expression in the cell lines used for flow cytometry in this study. Different cell lines (HEK293T, HEK293T_shRNAp53,
SH-SY5Y, NLF and SK-N-AS) were transfected with plasmids expressing either EGFP-luciferase or EGFP-NBPF1 in order to investigate cell cycle distribution.
As a control for efficient transfection and expression of EGFP-luciferase or EGFP-NBPF1, we took a fraction of the cells and prepared equal amounts of total
cellular lysates for SDS-PAGE. These lysates were immunoblotted with an anti-NBPF antibody (sc-82241) to detect overexpressed NBPF1 protein, with an
anti-EGFP antibody to detect the fusion proteins EGFP-luciferase (indicated by *) and EGFP-NBPF1 (indicated by **), or with an anti-actin antibody, which
served as a loading control. All cell lines transfected for flow cytometry analysis showed effective expression of EGFP-luciferase or EGFP-NBPF1 proteins
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an EGFP-fused NBPF1 protein: there was a clear overlap
between the EGFP signal and sc-82241 reactivity (Fig. 1A).
We then stained the inducible DLD1Tr21/NBPF1 stable
cell line [3]: sc-82241 reactivity was observed only in the
presence of doxycycline (dox), implying NBPF1-specific
recognition (Fig. 1B). Taken together, these experimentsclearly show that sc-82241 specifically detects human
NBPF proteins.
Staining of human skin sections with the anti-NBPF
antibody revealed a strong and specific staining of the
suprabasal layer of the epidermis (Fig. 1C, left panel), in
contrast to the proliferating basal layer [14, 15]. The
mouse genome does not contain NBPF genes, and
Fig. 6 NBPF1 overexpression increases CDKN1A transcript levels. HEK293T cells were transfected with plasmids encoding either EGFP-luciferase or
EGFP-NBPF1. Both EGFP-positive (+) and EGFP-negative populations (−) were isolated by FACS, and the expression levels of important cell cycle
related genes were determined by real-time qRT-PCR. The values of EGFP-luciferase negative cells were set to 1. p-values were calculated with
one-way ANOVA; ns: not significant
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layers of mouse skin (Fig. 1C, right panel). We thus
conclude that the observed staining in human skin is
specific for NBPF. Additionally, we used this antibody
to stain human cervix, another tissue with a squamous
epithelium. Although the staining was less homoge-
neous here, we also found the strongest signal in the
suprabasal layer in contrast to the proliferative basal
layer (Fig. 1D).NBPF1 inhibits cell cycle progression in transfected
human embryonic kidney cells
Tumor suppressor genes are vital for counteracting the
formation and progression of cancers. Therefore, such
genes generally function to slow down cell division, re-
pair DNA errors or trigger apoptotic pathways [16]. We
previously reported that NBPF1 induction suppresses an-
chorage-independent growth [3]. Moreover, the abovemen-
tioned expression of NBPF in suprabasal, non-proliferating
Fig. 7 NBPF1 overexpression increases p21CIP1/WAF1 protein levels. (A) HEK293T cells were transfected with plasmids encoding either EGFP-luciferase or
EGFP-NBPF1. Both EGFP-positive (+) and EGFP-negative populations (−) were isolated by FACS, and the protein levels of p21CIP1/WAF1 were detected by
western blotting (top row). Treatment of cells with doxorubicin (+ Doxo) served as a positive control for p21 induction. Detection with the anti-NBPF
antibody (sc-82241) showed the successful isolation of EGFP-NBPF1 transfected cells (second row). Detection with an anti-EGFP antibody (third row)
showed successful isolation of transfected cells that were EGFP-luciferase positive (indicated by *) or EGFP-NBPF1 positive (indicated by **).
Vinculin expression acted as a loading control (bottom row). (B) Quantification of p21CIP1/WAF1 signals in the blot of (A), normalized against
vinculin signals. In addition to the positive control (+ Doxo), only cells expressing EGFP-NBPF1 showed clear induction of p21. p-values
were calculated with one-way ANOVA
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between NBPF expression and inhibition of cell prolifera-
tion. This prompted us to explore the role of NBPF1 ex-
pression during the cell cycle.
Therefore, we investigated the spatio-temporal dynam-
ics of NBPF1 expression in the human embryonic kidney
cell line, HEK293T. These cells were transfected with a
control chimeric EGFP-luciferase expressing plasmid or
with a plasmid expressing a chimeric EGFP-NBPF1 pro-
tein. EGFP fluorescence for both setups was followed in
real-time. Interestingly, striking differences were seen
between the control cells and the EGFP-NBPF1 positive
cells. Whereas EGFP-luciferase expression remained at a
constant level for at least 15 h (Fig. 2A and representa-
tive movie in Additional file 1: Movie 1), EGFP-NBPF1
expression often decreased rapidly (Fig. 2B and repre-
sentative movie in Additional file 2: Movie 2). Also, we
observed cells in the EGFP-NBPF1 setup that were
EGFP negative at the onset of the experiment, but be-
came EGFP positive later on. Importantly, we never ob-
served any cell expressing EGFP-NBPF1 that completed
a full cell cycle, whereas untransfected cells and EGFP-
luciferase-transfected control cells divided frequently.Therefore, we hypothesized that the cell cycle was
arrested in EGFP-NBPF1 positive cells, at least during
the period of examination. Additionally, the disappear-
ance of EGFP-NBPF1 positive cells suggested that the
protein was degraded in proliferating cells. To further
investigate this, we induced growth arrest by using a
chemotherapeutic agent, aphidicolin, which is an inhibi-
tor of eukaryotic nuclear DNA replication and blocks
the cell cycle at the early S phase. HEK293T cells were
transfected with an EGFP-luciferase control plasmid or
with a plasmid expressing a chimeric EGFP-NBPF1 pro-
tein. After 24 h, the cells were treated with aphidicolin
and EGFP fluorescence for both setups was followed in
real-time 24 h later. Strikingly, EGFP-NBPF1 expression
did not decrease but the protein accumulated in the
form of particulate or aggregated structures during the
time of imaging (Fig. 3B and representative movie in
Additional file 3: Movie 3) whereas EGFP-luciferase
expression remained at a constant level and no aggre-
gates were seen (Fig. 3A and representative movie in
Additional file 4: Movie 4). Therefore, we hypothesized
that NBPF1 expression is indeed lost in proliferating
cells, and that upon artificial induction of a cell cycle
Fig. 8 (See legend on next page.)
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Fig. 8 NBPF1 overexpression induces nuclear accumulation of p53 as well as p53-dependent cell cycle arrest and CDKN1A induction. (A) HEK293T
cells were transfected with a plasmid encoding either EGFP-luciferase (top panels) or EGFP-NBPF1 (lower panels). Immunofluorescence at 48 h
after transfection for p53 revealed an increased accumulation in the nucleus upon EGFP-NBPF1 transfection. Nuclei were counterstained with
DAPI. Scale bars: 10 μm. (B) HEK293T_shRNAp53 cells were transfected with plasmids encoding either EGFP-luciferase or EGFP-NBPF1. Cell cycle
profiles were determined 48 h after transfection by flow cytometry on the effectively transfected (EGFP-positive) cell subpopulations. Transfection
efficiency is represented as percentage in the left panels. The different cell cycle phases are shown only for the effectively transfected (EGFP-positive)
subpopulations (right panels). Cells in G1 phase (2n DNA content) and cells in G2 phase (4n content) are annotated on the histograms and calculated
as percentage of the whole population. NBPF1 overexpression does not induce G1 cell cycle arrest in HEK293T cells with stable knockdown of p53. (C)
HEK293T and HEK293T_shRNAp53 cells were transfected with plasmids encoding either EGFP-luciferase or EGFP-NBPF1. Both EGFP-positive (+) and
EGFP-negative populations (−) were isolated by FACS, and the expression levels of CDKN1A transcripts were determined by real-time qRT-PCR.
EGFP-NBPF1 expression induced CDKN1A transcripts only in HEK293T cells. p-values were calculated with one-way ANOVA; ns: not significant
Andries et al. BMC Cancer  (2015) 15:391 Page 13 of 25block, NBPF1 escapes degradation but loses its func-
tionality due to its aggregation. Taken together, these
data indicate that NBPF1 overexpression affects cell
cycle and cell fate, and reveal that NBPF1 expression is
cell cycle dependent: expression occurs mainly in G1
and is lost during mitosis.
Further, we examined the effects of NBPF1 overexpres-
sion on cell cycle progression by flow cytometry. We
transiently overexpressed either EGFP-luciferase or EGFP-
NBPF1 in HEK293T cells and 48 h after transfection, cells
were fixed, stained with propidium iodide and cell cycle
profiles were examined for successfully transfected cells
(Fig. 4, left panels; 48.5% EGFP-positive cells for EGFP-
luciferase expressing cells; 54.2% for EGFP-NBPF1 ex-
pressing cells). This experiment clearly demonstrated that
EGFP-NBPF1 overexpression blocked cells in the G1
phase of the cell cycle (Fig. 4, right panels). As a control
for efficient EGFP-NBPF1 expression we determined the
protein levels of NBPF1 and confirmed that, as expected,
only cells transfected with EGFP-NBPF1 showed strong
NBPF1 expression, whereas cells transfected with EGFP-
luciferase did not (Fig. 5).Fig. 9 NBPF1 overexpression has no effect on the mRNA levels of the TP53
plasmids encoding either EGFP-luciferase or EGFP-NBPF1. Both EGFP-positiv
the expression levels of TP53 were determined by real-time quantitative RTNBPF1 inhibits cell cycle progression in HEK293T cells by
increasing p21CIP1/WAF1 levels in a p53-dependent manner
To gain more insight into the mechanism of the G1 ar-
rest upon NBPF1 expression, we assessed the expression
of several genes known to be important in the cell cycle.
HEK293T cells were transfected with plasmids encoding
either EGFP-luciferase or EGFP-NBPF1. 48 hours later,
EGFP-positive and EGFP-negative populations from
both settings were isolated by FACS (fluorescence-acti-
vated cell sorting). For all populations, we investigated
by real-time quantitative RT-PCR (qRT-PCR) the expres-
sion profile of a panel of relevant genes. We focused on
genes that are master regulators of the G1 phase or the
G1-to-S transition (ANAP2, CCND1, CCNE1, CDC34,
CDK2, CDK4, CDK6, CUL1, CUL2, CUL3, SKP2), and
on genes important in cell cycle checkpoints (ATM,
ATR) and cell cycle arrest (CDKN1A, CDKN1B). This
profiling showed that expression of NBPF1 led to a re-
producible 2.5-fold increase in CDKN1A mRNA, which
encodes the cell cycle inhibitor p21CIP1/WAF1 (Fig. 6).
This increase was seen only in EGFP-NBPF1-positive
cells and not in the control or mock transfected cells.gene. HEK293T and HEK293_shRNAp53 cells were transfected with
e (+) and EGFP-negative populations (−) were isolated by FACS and
-PCR
Fig. 10 NBPF1 induces cell death in an NB cell line with wild-type p53 and inhibits cell cycle progression in NB cell lines with mutated p53. Three
different NB cell lines were transfected with plasmids encoding either EGFP-luciferase (left panels) or EGFP-NBPF1 (right panels) and cell cycle
profiles were analyzed 48 h post-transfection. Transfection efficiency is represented as percentage in the left panels. The different cell cycle
phases are shown only for the effectively transfected (EGFP-positive) subpopulations (right panels). Cells in G1 phase (2n DNA content) and
cells in G2 phase (4n content) are annotated on the histograms and calculated as percentage of the whole population. Overexpression of
NBPF1 in SH-SY5Y cells, bearing a wild-type TP53 gene, does not result in G1 cell cycle arrest, but induces cell death (sub-G1 peak, indicated
by arrow) (top panel). Overexpression of NBPF1 in two NB cell lines, NLF (middle panel) and SK-N-AS (bottom panel), with mutated p53 induces G1 cell
cycle arrest
Andries et al. BMC Cancer  (2015) 15:391 Page 14 of 25The profiling also showed a modest NBPF1-induced up-
regulation of the mRNA levels of ANAP2, CDC34 and
CDKN1B. However, in contrast to the obvious and re-
producible CDKN1A induction, the upregulation of
these three genes turned out to be poorly reproducible
(data not shown). As a control for efficient transfection
and cell sorting, we determined the mRNA expression
levels of NBPF1 and confirmed that, as expected, only
the EGFP-positive population of cells transfected with
EGFP-NBPF1 showed strong NBPF1 expression, whereasthe EGFP-negative populations and both populations
transfected with EGFP-luciferase did not (data not
shown).
In addition, protein lysates of EGFP-positive and
EGFP-negative populations from both settings showed
that not only the CDKN1A mRNA levels, but also the
p21CIP1/WAF1 protein levels were upregulated upon
NBPF1 overexpression in HEK293T cells (Fig. 7). Doxo-
rubicin (Doxo) treatment of mock transfected cells
served as a positive control for p21CIP1/WAF1 induction.
Fig. 11 (See legend on next page.)
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Fig. 11 NBPF1 overexpression increases p21CIP1/WAF1 protein levels in NB cell lines with mutant p53. (A) SH-SY5Y, NLF and SK-N-AS cells were
transfected with plasmids encoding either EGFP-luciferase or EGFP-NBPF1. Both EGFP-positive (+) and EGFP-negative populations (−) were isolated
by FACS, and the protein levels of p21CIP1/WAF1 were detected by western blotting (top row). Treatment of HEK293T cells with doxorubicin (+ Doxo)
served as a positive control for p21 induction. Detection with the anti-NBPF antibody (sc-82241) showed successful isolation of EGFP-NBPF1 transfected
cells (second row). Detection with an anti-EGFP antibody (third row) showed successful isolation of transfected cells that were EGFP-luciferase positive
(indicated by *) or EGFP-NBPF1 positive (indicated by **). Actin expression acted as a loading control (bottom row). (B) Quantification of p21CIP1/WAF1
signals in the blot of (A), normalized against actin signals. In addition to the positive control (HEK293T + Doxo), only NB cells with mutant p53 expressing
EGFP-NBPF1 showed clear induction of p21. p-values were calculated with one-way ANOVA
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pression in HEK293T cells induces p21CIP1/WAF1 expres-
sion at both the mRNA and protein levels.
To examine whether the upregulation of CDKN1A
upon NBPF1 expression was p53-dependent, we ana-
lyzed p53 expression in HEK293T cells transfected with
plasmids encoding either EGFP-luciferase or EGFP-NBPF1.
48 hours later, we performed immunofluorescence for
EGFP and p53 and observed that the overexpression of
NBPF1 resulted in increased nuclear accumulation of p53
in comparison with the EGFP-luciferase transfected con-
trol cells (Fig. 8A). To confirm the role of p53 by a differ-
ent approach, we used HEK293T cells in which p53 had
been stably silenced (HEK293T_shRNAp53). We first in-
vestigated the different cell cycle phases upon overexpres-
sion of EGFP-luciferase or EGFP-NBPF1. This experiment
showed that in HEK293T cells with stable knockdown of
p53, NBPF1 overexpression does not result in a G1 cell
cycle arrest (Fig. 8B). As a control for efficient EGFP-
NBPF1 expression, we determined the protein levels of
NBPF1 and confirmed that, as expected, only cells trans-
fected with EGFP-NBPF1 showed strong NBPF1 expres-
sion, whereas cells transfected with EGFP-luciferase did
not (Fig. 5).
In addition, we investigated whether overexpression
of NBPF1 in this modified cell line still results in the
upregulation of CDKN1A mRNA levels. HEK293T (no
silencing of p53) and HEK293T_shRNAp53 cells were
transfected with plasmids encoding either EGFP-lucif-
erase or EGFP-NBPF1. EGFP-positive and EGFP-nega-
tive populations from both settings were isolated by
FACS, and then mRNA expression levels of CDKN1A
were investigated by real-time qRT-PCR in all
populations. Whereas NBPF1 overexpression in wild
type cells resulted in upregulation of CDKN1A mRNA
levels, as initially observed, this was not the case when
p53 had been silenced (Fig. 8C). Additionally, NBPF1
overexpression did not influence TP53 mRNA levels,
neither in HEK293T nor in HEK293T_shRNAp53 cells
(Fig. 9).
Together, these data indicate that overexpression of
NBPF1 in HEK293T cells results in a p53-dependent
induction of CDKN1A and cell cycle arrest.NBPF1 overexpression in neuroblastoma cell lines
The human NBPF1 gene was originally identified in a
NB patient on the basis of its disruption in a de novo,
constitutional translocation between chromosomes
1p36.2 and 17q11.2 [1-3]. Moreover, we reported that
expression of NBPF1 mRNA is significantly decreased in
NB cell lines with loss of heterozygosity for 1p36 com-
pared to cell lines with a normal 1p36 locus [3]. This de-
creased expression is a hallmark of tumor suppression
activity, which motivated us to investigate whether NBPF1
overexpression arrests the cell cycle also in neuroblastoma
cell lines. Hence, we overexpressed EGFP-luciferase or
EGFP-NBPF1 in three different NB cell lines (SH-SY5Y,
NLF and SK-N-AS) and 48 h after transfection we ana-
lyzed the cell cycle profiles of the positively-transfected
cell populations. SH-SY5Y is a NB cell line bearing wild-
type TP53, whereas NLF and SK-N-AS show a TP53 loss-
of-function mutation due to, respectively, a missense
mutation in exon 6 (607G >A) and a homozygous dele-
tion of exons 10 and 11 [12]. Interestingly, EGFP-NBPF1
overexpression arrested the cell cycle in the G1 phase in
the two p53-mutant NB cell lines, whereas overexpression
of EGFP-NBPF1 in the SH-SY5Y NB cell line, with a wild-
type TP53, resulted in a marked sub-G1 peak, indicating
induction of cell death (Fig. 10). As a control for efficient
EGFP-NBPF1 expression, we determined the protein levels
of NBPF1 and confirmed that, as expected, only cells trans-
fected with EGFP-NBPF1 expressed NBPF1, whereas cells
transfected with EGFP-luciferase did not (Fig. 5).
Moreover, analysis of protein lysates of EGFP-positive
and EGFP-negative subpopulations from both settings of
the three NB cell lines showed that the p21CIP1/WAF1
protein levels were upregulated upon NBPF1 overex-
pression in NLF and SK-N-AS cells, in line with the ob-
served G1 cell cycle block, but not in SH-SY5Y cells
(Fig. 11). We also performed immunofluorescence for
EGFP, NBPF1 and p53 in order to check whether the
overexpression of NBPF1 resulted in nuclear accumula-
tion of p53. However, we did not observe marked nu-
clear accumulation of p53 upon NBPF1 overexpression
in either NB cell line (Fig. 12).
Together, these data indicate that NBPF1 overexpres-
sion in NB cell lines with non-functional p53 results in
Fig. 12 NBPF1 overexpression induces no nuclear accumulation of p53 in NB cell lines. SH-SY5Y, NLF and SK-N-AS cells were transfected with a plasmid
encoding either EGFP-luciferase (top panel) or EGFP-NBPF1 (lower panel). Immunofluorescence for p53 revealed no increased accumulation in the nucleus
upon EGFP-NBPF1 transfection in either cell line. EGFP-luciferase transfected cells were stained with an anti-EGFP antibody, whereas EGFP-NBPF1
transfected cells were stained with the anti-NBPF antibody sc-82241, both represented in green. Nuclei were counterstained with DAPI. Scale
bars: 10 μm
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Fig. 13 CDKN1A expression is not induced upon NBPF1 expression in DLD1Tr21/NBPF1 cells. Expression analysis of selected genes and proteins
was executed in DLD1Tr21/Mock and DLD1Tr21/NBPF1 cells, with or without dox treatment. Real-time quantitative RT-PCR measurements are
shown for the expression levels of the IRES-driven marker gene EGFP (A), NBPF1 (B) and CDKN1A (C). Cells analyzed were kept untreated (− dox)
or were dox treated for 8, 24 or 48 h in order to induce NBPF1 expression. CDKN1A mRNA induction upon NBPF1 expression was not observed in
the dox-induced DLD1Tr21/NBPF1 cells. (D) Western blot was performed with lysates of dox-treated and non-treated DLD1Tr21/Mock and
DLD1Tr21/NBPF1 cells. Cells were induced for 48 h and immunoblotted with an anti-p21 antibody. p21 protein induction was not observed in
dox-induced DLD1Tr21/NBPF1 cells. EGFP detection showed efficient dox-dependent induction in both cell lines. Actin detection was used as a
loading control
Andries et al. BMC Cancer  (2015) 15:391 Page 19 of 25G1 cell cycle arrest and induction of CDKN1A, whereas
overexpression of NBPF1 in a NB cell line with a wild-
type p53 triggers cell death without induction of
CDKN1A.
CDKN1A expression is not induced upon NBPF1
expression in DLD1Tr21/NBPF1 cells
We then investigated whether the NBPF1-dependent
CDKN1A induction could be confirmed in p53-mutant
DLD1Tr21/NBPF1 cells, in which we expect that NBPF1
plays a tumor suppressor role [3]. DLD1Tr21/NBPF1
and DLD1Tr21/Mock cells were induced with dox for 8,
24 or 48 h and the expression levels of CDKN1A, EGFP
and NBPF transcripts were determined by real-time
quantitative RT-PCR. This expression analysis confirmed
that DLD1Tr21/NBPF1 and DLD1Tr21/Mock cells
expressed EGFP upon dox addition (Fig. 13A), and that
NBPF1 expression was induced only in the DLD1Tr21/
NBPF1 cell line in the presence of dox (Fig. 13B). How-
ever, in this cell line we did not detect any NBPF1-
dependent changes in the mRNA level of CDKN1A
(Fig. 13C). In addition, protein lysates of induced
DLD1Tr21/NBPF1 cells showed that also the p21CIP1/WAF1
protein levels were not upregulated upon NBPF1 overex-
pression (Fig. 13D). Moreover, investigation of the differ-
ent cell cycle phases upon induction of NBPF1 showed no
changes in G1 or G2 phases (Fig. 14A), nor did we observe
nuclear accumulation of p53 upon NBPF1 induction
(Fig. 14B). These data indicate that the induction of
CDKN1A upon NBPF1 overexpression is cell-type specific,
and that the tumor suppressive effect of NBPF1 may act
with or without cell cycle arrest.
The proteome response of DLD1Tr21 cells upon
expression of NBPF1
To obtain complementary information with respect to
the role of NBPF1, we investigated the differences be-
tween the proteomes of DLD1Tr21/NBPF1 cells and
DLD1Tr21/Mock cells. Both cell types were grown for
4 days in the presence of dox in standard medium. Lysates
of the induced DLD1Tr21/Mock cells (Fig. 15; + dox, no
NBPF1 expression, only EGFP expression) were digested
with endoproteinase Lys-C and post-metabolically labeled
with light NHS-12C3-propionate [17]. On the other hand,lysates of the induced DLD1Tr21/NBPF1 cells (Fig. 15; +
dox, NBPF1 and EGFP expression) were labeled with
heavy NHS-13C3-propionate. LC-MS/MS analysis led to
the identification of 3613 proteins. A total of 32 proteins
showing differential expression was identified at the 99%
confidence level [18] (Additional file 5: Table S1). Of these
32 proteins, 19 proteins were upregulated, whereas 13
proteins were downregulated upon NBPF1 expression.
To investigate the possible biological interactions be-
tween the proteins that were differently regulated upon
NBPF1 expression, the proteomics data were imported
into the Ingenuity Pathway Analysis (IPA) tool. This
analysis revealed two networks that are significantly al-
tered upon NBPF1 expression, of which ‘cellular com-
promise, DNA replication and recombination’ was the
highest rated network, with 19 focus molecules and a
significance score of 49 (Fig. 16A). The IPA analysis also
grouped the genes that were differentially expressed
upon NBPF1 expression into a number of biological
mechanisms related to dermatological disease, inflamma-
tory disease, inflammatory response, cancer, and endo-
crine system disorders. Interestingly, 13 of the 14 genes
that were differentially expressed and implicated in cancer
(p-value ranging from 3.74E–4 to 4.77E–2) were present
in the highest rated network (Fig. 16B).
Discussion
We previously reported evidence for a tumor suppressor
role of NBPF1 [3]. However, the molecular mechanisms
responsible for its anti-tumor effect were not elucidated.
This paper shows that NBPF1 can exert its tumor sup-
pressive effect in different ways: by blocking cell division,
inducing cell death, or by modulating a cancer-associ-
ated proteome.
Live-cell imaging of the embryonic kidney cell line
HEK293T, transfected with an EGFP-NBPF1 expressing
construct, showed a temporally fluctuating pattern of
EGFP-NBPF1 expression in comparison with control
transfected cells continuously expressing EGFP-lucifer-
ase. In addition, we did not observe any EGFP-NBPF1
transfected cell that completed a cell cycle, whereas con-
trol EGFP-luciferase transfected cells and mock trans-
fected cells divided frequently. Analysis of the different
stages of the cell cycle in this cell line showed that
Fig. 14 (See legend on next page.)
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Fig. 14 Induced expression of NBPF1 in DLD1Tr21 cells does not result in a G1 cell cycle arrest or nuclear accumulation of p53. (A) Cell cycle
distribution of DLD1Tr21/Mock and DLD1Tr21/NBPF1 cells in the absence or presence of dox (48 h) shows no G1 arrest upon NBPF1 expression.
(B) Immunofluorescence for p53 revealed no increased accumulation in the nucleus upon NBPF1 expression. Expression of EGFP or NBPF1
(using antibody sc-82241) is induced upon treatment of the cells with dox for 48 h. Nuclei were visualized with DAPI. Scale bars: 10 μm
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comparison with the controls. In the HEK293T cells, this
arrest could be explained by the specific induction of
p21CIP1/WAF1, seen at both the mRNA and protein levels.
The best known activator of p21CIP1/WAF1 is the tumor
suppressor p53 [19]. Activation of p21 by p53 has indeed
been shown to play a key role in the ability of p53 to in-
duce cell cycle arrest [20]. Therefore, we performed ex-
periments to determine if NBPF1 was acting via p53
induction. First, we performed immunofluorescence for
p53 in HEK293T cells and showed an increased nuclear
accumulation of p53 upon overexpression of NBPF1,
whereas knock-down of p53 did not result in a G1 cell
cycle arrest and abolished NBPF1-induced CDKN1A ex-
pression. Still, the p53 status in HEK293T cells is contro-
versial as these cells express adenoviral proteins that
inhibit p53 activity. To clarify this controversy, we stim-
ulated HEK293T and DLD1Tr21 cells with an inducer of
DNA double-strand breaks, doxorubicin, which results
in p53-dependent upregulation of p21 [21]. Treatment
with doxorubicin induced p21 in the HEK293T cells, but
not in the DLD1Tr21 cell line with mutated TP53 (dataFig. 15 Immunofluorescent analysis of the DLD1Tr21/Mock and DLD1Tr21/
grown for 4 days in standard medium supplemented with dox. The induce
12C6-NHS-propionate, and the induced DLD1Tr21/NBPF1 cells were post-meta
proteomic analysis as described in Methods. As a control for proper NBPF1 in
NBPF1 expression by immunofluorescent microscopy. Expression of EGFP
dox (untreated cultures were fully negative). NBPF1 (antibody sc82241; re
the presence of dox. Nuclei were visualized with DAPI. Scale bars: 10 μmnot shown). Therefore, we concluded that the activity of
p53 is only attenuated in HEK293T cells, but not com-
pletely inhibited. This leads to transcriptional activation
of CDKN1A upon doxorubicin treatment, and therefore,
the induction of p21 upon overexpression of NBPF1 in
HEK293T cells can be considered to be p53-dependent.
Moreover, stable knockdown of p53 in HEK293T cells
completely abrogated the NBPF1-induced cell cycle
block and CDKN1A upregulation, thereby confirming
that NBPF1-induced cell cycle arrest is p53-dependent
in HEK293T cells.
Nuclear translocation of p53 indicates its activation
[22], and NBPF1 seems to act in HEK293T cells via in-
creasing the nuclear expression of p53. However, the
mechanism by which NBPF1 can modulate p53 remains
unknown. As NBPF1 proteins are located in the cyto-
plasm, whereas active p53 is in the nucleus, a direct
interaction between NBPF1 and p53 seems unlikely.
However, MDM2, the main inhibitor of p53 activity, is
located in the cytoplasm, and NBPF1 might interact with
MDM2, thereby preventing the negative effects of
MDM2 on p53. To test this hypothesis, we performedNBPF1 cell cultures used for proteomic analysis. Cell cultures were
d DLD1Tr21/Mock cells were post-metabolically labeled with light
bolically labeled with heavy 13C6-NHS-propionate, and then submitted to
duction, replicate cell cultures were stained for induction of EGFP and
(shown in green) is induced in both cell lines upon the addition of
d channel) was expressed only in DLD1Tr21/NBPF1 cells and only in
Fig. 16 Summary of Ingenuity Pathway Analysis (IPA). The dataset representing the 32 genes with significantly altered expression upon NBPF1
induction in DLD1Tr21 cells was imported into the IPA tool. (A) The top two networks obtained from the IPA analysis and their scores. (B)
Network presentation of the most highly rated network. Solid lines represent a direct interaction between two gene products and dotted lines
represent indirect interactions. Red symbols indicate input molecules that are downregulated upon NBPF1 expression, and green symbols
represent input molecules that are upregulated upon NBPF1 expression
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of both NBPF1 and MDM2 in HEK293T cells. Although
we could demonstrate a minor interaction between
NBPF1 and MDM2 (data not shown), we believe that thisinteraction is of insufficient extent to explain the observed
NBPF1-driven nuclear accumulation of p53. On the other
hand, it is possible that NBPF1 promotes the nuclear
localization of p53 via a posttranslational modification,
Table 2 Overview of shRNAs and siRNAs used in this study with the aim to silence the expression level of NBPF family members
Knockdown
type
# Target seq (5' to 3') Targets only NBPF1 Exon
typeNo Yes
shRNA_19-mer 1 CCUCUUCUGCCACAAACGUUU X 1
2 GGAAUGUGCCAUCACUUGU X 5
3 GGAAGUCCCUGAGGACUCA X 6
4 GAAGAAGAUCAACGAAGAA X 12
5 CUUACUUUGAUGGGAACAA X 14
shRNA_29-mer 6 UACCUCUUCUGCCACAAACGUCAGCAUGGU X 1
7 AUGUCAGGAUGCUGUAAACAUUCUCCCAG X 5
8 AACAUCAACAUCACCUUUGAGGAAGACAA X 5
9 UGACUCCAACCAGCCUCACAAGAACAUCA X 5
10 GGAGAAGACGGUGUACCAGCCUCACAAGA X 5
11 ACCAGUCUUACAGCGGCACAUUUCACUCA X 8
12 CCUGACUCAUUCCAGCACUACAGAAGUGU X 14
13 AGCUGGCAGAGAACAAACAGCAGUUCAGA X 1
14 AUGCUGAGGAAUGAGCGACAGUUCAAGGA X 2
15 UAAGGGAGAAGUUACGGGAAGGGAGAGAU X 3
16 CUUCCUGGCCAACCAGCAGAACAAAUACA X 1
siRNA pool 17 GAAUCGUACUGCUAAGAAU X 5' UTR
ACAGAGACAGACAAAGAUA X 5' UTR
GAUGGCCAAUCUUUCCUAA X 5' UTR
GCAAGUCCAGGUCAUACUG X 5' UTR
Given are the target sequence, the predicted specificity (NBPF1-specific or broad NBPF specificity) and location in exons (for exon type, see ref. [4]) or 5’UTR.
shRNAs 1 to 5 represent shRNAs with a stem length of 19 bps, whereas shRNAs 6 to 16 represent shRNAs with a stem length of 29 bps. For shRNAs 1 to 8, the
expression cassettes of the shRNAs were created by us by a double PCR-approach, whereas shRNAs 9 to 16 are HuSH retroviral silencing vectors from Origene
(Origene Technologies, Rockville, MD, USA). siRNA pool 17 represents an On-Target plus siRNA pool from Dharmacon (Thermo Fisher Scientific, Lafayette, CO, USA)
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experiments are required to elucidate this.
The human NBPF1 gene was originally identified in a
NB patient [1-3], and we reported previously that ex-
pression of NBPF1 mRNA is significantly decreased in
NB cell lines with loss of heterozygosity for 1p36 com-
pared to cell lines with a normal 1p36 locus [3]. There-
fore, we investigated the role of NBPF1 in several NB
cell lines, both with mutant or wild-type TP53 alleles.
Overexpression of NBPF1 in NLF and SK-N-AS resulted
in a G1 cell cycle arrest and in CDKN1A upregulation.
NLF and SK-N-AS bear loss-of-function mutations of
TP53, namely, a missense mutation in the TP53 exon 6
(607G > A) of NLF cells, and a homozygous deletion of
TP53 exons 10 and 11 of SK-N-AS cells [12]. These re-
sults indicate that the G1 cell cycle arrest is p53-
independent or that these mutant p53 proteins can still
induce p21. Stable knockdown of p53 in these NB cell
lines is required to confirm that NBPF1-induced cell
cycle arrest is p53-independent in these NB cell lines.
Surprisingly, overexpression of NBPF1 in the SH-SY5Y
cell line, expressing wild-type p53, did not result in a G1cell cycle arrest, but led to the appearance of a sub-G1
peak, indicative of induced cell death. Therefore, we
hypothesize that the growth-inhibitory effect upon
NBPF1 overexpression is p21-dependent, and that over-
expression of NBPF1 in the SH-SY5Y cell line does not
result in G1 arrest due to lack of p21 induction.
The observed arrest of the cell cycle by overexpression
of NBPF1 is in line with the apparent expression of
NBPF family members in the non-proliferating supraba-
sal layers of squamous stratified tissues, whereas the
basal layers with proliferating cells are essentially NBPF-
negative. We demonstrated this by immunohistochemis-
try using a polyclonal antibody after having clearly dem-
onstrated its specificity for NBPF proteins. This
commercial antibody might therefore be used in future
studies on NBPF expression in human tumor samples.
We could not confirm NBPF1-dependent CDKN1A
upregulation in DLD1Tr21/NBPF1 colon cancer cells.
Our proteome analysis of DLD1 cells with induced
NBPF1 expression indicates that the absence of a cell cycle
arrest in these cells might be due to the upregulation of
several cell-cycle promoting genes, such as EEF1A2 and
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lated by NBPF1 or whether their upregulation represents
compensatory effects counteracting NBPF1 function in
DLD1 cells needs further investigation. In any case, these
data indicate that the proposed tumor suppressive proper-
ties of NBPF1 might be very versatile and cell-specific.
Despite the lack of CDKN1A upregulation in DLD1
cells with inducible NBPF1 expression, these cells show
a marked decrease of clonal growth in a soft agar assay
upon NBPF1 induction [3]. Anchorage-independent
growth of cells is one of the hallmarks of cellular trans-
formation and is regarded as a critical step during metas-
tasis [26]. Intriguingly, VCP (valosin-containing protein),
which is associated with anti-apoptotic functions and me-
tastasis via activation of the NF-κB signaling pathway [27],
was significantly downregulated upon NBPF1 expression
in DLD1 cells. Moreover, NBPF1 induction decreased the
expression of S100P, the expression of which is associated
with drug resistance, metastasis, and poor clinical out-
come in many different cancers such as colon, breast and
prostate cancer [28]. Also, overexpression of S100P in PC3
prostate cancer cells promotes anchorage-independent
growth in soft agar [29].
Both overexpression and knockdown strategies are com-
monly used to scrutinize gene functions. Thus, knock-
down of NBPF1 would have been a complementary
approach to the experiments described here. We used sev-
eral approaches and numerous attempts to knock down
the expression of the NBPF1 gene or the NBPF gene family
in human cells (Table 2). On the one hand, we aimed at
silencing specifically the NBPF1 gene. On the other hand,
we tried to silence the NBPF gene family as a whole be-
cause downregulation of only NBPF1 might lead to com-
pensation by NBPF paralogs having overlapping functions
and therefore obscure the phenotype. However, none of
the many siRNAs and shRNAs tested showed an accept-
able knockdown level for silencing endogenous NBPF,
which has prevented us so far from proceeding with func-
tional studies.
Conclusions
We have shown that NBPF1 can act as a tumor suppressor
by inhibiting the cell cycle, by cell death induction or
by expression modulation of various proteins implicated
in cancer. This may occur via either p53-dependent or
p53-independent mechanisms, depending on the cell type.
Therefore, disruption of the NBPF1 gene in neuroblastoma
patients, and possibly in other cancers as well, can result
in several dysregulations of cellular activity and thereby
contribute to the initiation or progression of cancer.
This study is among the first molecular analyses of the
tumor suppressor functions of NBPF proteins. Further
progress in the functional characterization of these intri-
cate proteins, which probably have important roles inhuman cancer, should help us to improve human cancer
diagnosis and prognosis, and to develop more effective
therapeutic strategies.Additional files
Additional file 1: Movie 1. Fluorescence time lapse microscopy of
HEK293T cells expressing EGFP-luciferase. EGFP-luciferase expression was
followed for 15 h with images captured every 10 min. Fluorescence levels
are represented by pseudocolors, where blue indicates low EGFP levels
and yellow indicates high EGFP levels. EGFP-luciferase expression
remained constant during time lapse microscopy. Cells regularly
underwent mitosis.
Additional file 2: Movie 2. Fluorescence time lapse microscopy of
HEK293T cells expressing EGFP-NBPF1. EGFP-NBPF1 expression was
followed for 15 h with images captured every 10 min. Fluorescence levels
are represented by pseudocolors, where blue indicates low EGFP levels
and yellow indicates high EGFP levels. EGFP-NBPF1 expression decreased
rapidly or EGFP-negative cells became modestly EGFP-positive during the
experiment. EGFP-NPBP1 expressing mitotic cells successfully completing
mitosis were never observed.
Additional file 3: Movie 3. Fluorescence time lapse microscopy of
HEK293T cells stimulated with aphidicolin and expressing EGFP-NBPF1.
EGFP-NBPF1 expression was followed for 15 h with images captured
every 10 min. Fluorescence levels are represented by pseudocolors,
where blue indicates low EGFP levels and yellow indicates high EGFP
levels. EGFP-NBPF1 expression increased during the experiment and
protein aggregates were formed.
Additional file 4: Movie 4. Fluorescence time lapse microscopy of
HEK293T cells stimulated with aphidicolin and expressing EGFP-luciferase.
EGFP-luciferase expression was followed for 15 h with images captured
every 10 min. Fluorescence levels are represented by pseudocolors,
where blue indicates low EGFP levels and yellow indicates high EGFP
levels. EGFP-luciferase expression remained constant during time lapse
microscopy.
Additional file 5: Table S1. List of differential protein candidates upon
NBPF1 expression. 32 proteins showing differential expression were
identified at the 99 % confidence interval. Accession number, peptide
number, gene name, protein description, fold change and peptide
sequences are shown in the table. Proteins that are up or down
regulated upon NBPF1 expression are shown in green and red,
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